Gilead Sciences (GILD) : Rdl Financial Inc scooped up 248 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 38,766 shares of Gilead Sciences which is valued at $3,419,549.Gilead Sciences makes up approximately 2.55% of Rdl Financial Inc’s portfolio.
Gilead Sciences opened for trading at $88.7 and hit $89.45 on the upside on Monday, eventually ending the session at $89, with a gain of 0.90% or 0.79 points. The heightened volatility saw the trading volume jump to 1,35,24,049 shares. Company has a market cap of $121,649 M.
Other Hedge Funds, Including , Millie Capital Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 24,456 shares of GILD which is valued $2,157,264.Paradigm Financial Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 642 additional shares and now holds a total of 55,228 shares of Gilead Sciences which is valued at $5,629,390. Gilead Sciences makes up approx 3.41% of Paradigm Financial Advisors’s portfolio.Redwood Investments boosted its stake in GILD in the latest quarter, The investment management firm added 4,580 additional shares and now holds a total of 166,653 shares of Gilead Sciences which is valued at $16,986,940. Gilead Sciences makes up approx 1.67% of Redwood Investments’s portfolio.Stokes Hubbell Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 409 additional shares and now holds a total of 3,017 shares of Gilead Sciences which is valued at $307,523. Gilead Sciences makes up approx 0.14% of Stokes Hubbell Capital Management’s portfolio.Yhb Investment Advisors reduced its stake in GILD by selling 347 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 48,767 shares of GILD which is valued at $4,970,820. Gilead Sciences makes up approx 1.32% of Yhb Investment Advisors’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.